Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

What's Going On With Moderna Stock Wednesday?

Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know.

Benzinga

Moderna Stock Is Moving Higher Tuesday: Here's Why

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 variant of COVID-19.

Benzinga

Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga

Is Moderna Stock Underperforming the S&P 500?

With Moderna heavily lagging behind the broader S&P 500 Index, Wall Street appears cautious about this stock.

Barchart

Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works

Former Centers for Disease Control and Prevention immunizations chief Demetre Daskalakis said Sunday he resigned because politics has overrun science at the nation's top public-health agency, warning he "only see[s] harm coming" under Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga

FDA approves updated COVID-19 shots but limits access for some kids and adults

The Food and Drug Administration has approved updated COVID-19 vaccines for the upcoming fall and winter season

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'

The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga

Moderna Stock Is Trading Higher Friday: What's Going On?

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine.

Benzinga

FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply

View Preview

Benzinga

How RFK Jr is systematically undermining vaccines around the world

Vaccines are one of the greatest public health success stories of all time. Over the past 50 years, they’ve saved an estimated 154 million lives. But in the US, both access to vaccines and public trust in them are being systematically undermined – not by conspiracy theorists online, but from…

The Conversation

RFK Jr has slashed vaccine research. You need to know how perilous that is for the world

The avian flu virus is now just one mutation away from easier transmission among humans. Trump’s health chief is a grave risk to world health, says Prof Devi Sridhar, chair of global public health at the University of Edinburgh

The Guardian - UK

IBM and Moderna have simulated the longest mRNA pattern without AI — they used a quantum computer instead

Scientists used IBM's R2 Heron quantum processor to predict the secondary protein structure of a 60-nucleotide-long mRNA sequence.

LiveScience

Pfizer Covid vaccine for young children may not be renewed by FDA

Email obtained by Guardian says Pfizer was told approval may not be granted, meaning Moderna may have to fill gap

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here?

With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for investors?

Fortune

AI is already changing the corporate org chart

AI isn't just a new tool for the modern workplace; it's quietly reshaping how companies are organized.

The Independent UK

Doctors decry RFK Jr decision to slash mRNA vaccine grants: ‘Our nation will pay in lives’

‘A tremendous step backward, the politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and science denialist, is now making policy,’ one doctor said

The Guardian - UK

Despite RFK’s funding block, mRNA vaccines are too impressive to ignore

Scientists fear decision may increase vaccine hesitancy, but other countries are still willing to invest in research

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million, marking a major policy shift under Secretary Robert F. Kennedy Jr. that directly affects pharmaceutical giants like Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA).

Barchart

Moderna Stock: Is Wall Street Bullish or Bearish?

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Benzinga

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector

Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast.

Benzinga

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Benzinga

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna, Inc. (NASDAQ:MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.

Benzinga

Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

Barchart

1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so again.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

320 stories

Pfizer Inc

313 stories

Health and Human Services

291 stories

the University of Edinburgh

261 stories

MRNA

223 stories

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.